IN8bio Achieves 18× Intratumoral CD8+ Boost and 97% PFS Gain in glioblastoma
IN8bio’s translational data show multidose DeltEx DRI preserved CD3+, CD4+, CD8+ and γδ T cells during TMZ therapy and drove an 18× intratumoral CD8+ T cell increase with 90% granulocyte reduction. These immune changes align with mPFS of 13.0 months versus 6.6 months and mOS exceeding 17.2+ months.
1. Translational Data Highlights
IN8bio’s translational analysis integrates AI, immunogenomics, histopathology and spatial transcriptomics to reveal that repeated DeltEx DRI dosing preserves CD3+, CD4+, CD8+ and γδ T cells and drives profound remodeling of the glioblastoma microenvironment.
2. Survival Outcomes Improvement
Phase 1/2 findings demonstrate that multidose DeltEx DRI achieves a median progression-free survival of 13.0 months versus 6.6 months for standard-of-care, representing a 97% improvement, and extends median overall survival beyond 17.2+ months compared to 13.2 months.
3. Immune Landscape Remodeling
Spatially resolved analyses show an 18× increase in intratumoral CD8+ T cell density and a 90% reduction in granulocyte populations. Quantitative correlations link higher cumulative γδ T cell exposure and robust CD4+ T cell reconstitution with enhanced patient survival.
4. Biomarker and Trial Implications
A composite immune score separating higher- and lower-survival groups establishes a framework for biomarker-driven patient stratification. These mechanistic insights inform dosing optimization and pave the way for future DeltEx DRI study designs in solid tumors.